Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 259)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 05.05.24 17:10:19 von
neuester Beitrag 05.05.24 17:10:19 von
Beiträge: 2.941
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 2
Gesamt: 345.891
Gesamt: 345.891
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,2800
USD
-3,03 %
-0,0400 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,230 | +447,06 | |
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9923 | -16,61 | |
| 5,2500 | -19,23 | |
| 0,7500 | -48,28 |
Beitrag zu dieser Diskussion schreiben
Feedback
Gut das ich zu USD 4.14 nachgelegt habe 
Heute 5.20 +0.27 (5.38%)
Heute 5.20 +0.27 (5.38%)
http://finance.yahoo.com/news/orexo-full-report-january-dece…
Our other key product, Abstral, continued to develop positively during 2013 in Europe and towards end of the year also in the US. The US partner for Abstral, Galena Biopharma Inc., has already demonstrated that they can drive market share growth, as Abstral reached about five percent share of total prescription in the beginning of 2014 – 7 months from the contract was signed. Abstral was also approved and launched in Japan by Kyowa Hakko Kirin during the year and we look forward to a similar success on this market.
Our other key product, Abstral, continued to develop positively during 2013 in Europe and towards end of the year also in the US. The US partner for Abstral, Galena Biopharma Inc., has already demonstrated that they can drive market share growth, as Abstral reached about five percent share of total prescription in the beginning of 2014 – 7 months from the contract was signed. Abstral was also approved and launched in Japan by Kyowa Hakko Kirin during the year and we look forward to a similar success on this market.
Galena Biopharma Has A Promising Pipeline For Revenue Growth
http://seekingalpha.com/article/1994641-galena-biopharma-has…
http://seekingalpha.com/article/1994641-galena-biopharma-has…
Antwort auf Beitrag Nr.: 46.403.758 von lunatics am 07.02.14 19:39:54wo steht das?
Heute 5 überschritten.
Insider kaufen.
Insider kaufen.
Trading Spotlight
So jetzt gehts aber ab !
Huge Upside Potential
Galena Biopharma may be the home run that biotech investors are looking for. The stock is Buy rated at Maxim Group and Noble Financial, which both recently raised their price targets. With an FDA-approved pain medication, a partnership with generic giant Teva Pharmaceuticals and a superior pipeline, the stock may be an acquisition target. After a huge rise, the stock took a hit when CNBC’s Jim Cramer urged viewers to take profits. The company also had a bear raid from a short seller that was quickly refuted by the CEO. The lowered price may offer new money a solid entry point. The Maxim price target is $11, and the consensus target is at $7.33. Shares closed Thursday at $4.27.
Huge Upside Potential
Galena Biopharma may be the home run that biotech investors are looking for. The stock is Buy rated at Maxim Group and Noble Financial, which both recently raised their price targets. With an FDA-approved pain medication, a partnership with generic giant Teva Pharmaceuticals and a superior pipeline, the stock may be an acquisition target. After a huge rise, the stock took a hit when CNBC’s Jim Cramer urged viewers to take profits. The company also had a bear raid from a short seller that was quickly refuted by the CEO. The lowered price may offer new money a solid entry point. The Maxim price target is $11, and the consensus target is at $7.33. Shares closed Thursday at $4.27.
Galena Biopharma Inc. (NASDAQ: GALE)may be the home run that biotech investors are looking for.
The stock is Buy rated at Maxim Group and Noble Financial, which both recently raised their price targets. With an FDA-approved pain medication, a partnership with generic giant Teva Pharmaceuticals and a superior pipeline, the stock may be an acquisition target. After a huge rise, the stock took a hit when CNBC’s Jim Cramer urged viewers to take profits. The company also had a bear raid from a short seller that was quickly refuted by the CEO.
The lowered price may offer new money a solid entry point.
The Maxim price target is $11, and the consensus target is at $7.33. Shares closed Thursday at $4.27.
http://247wallst.com/healthcare-business/2014/02/07/eight-bi…
The stock is Buy rated at Maxim Group and Noble Financial, which both recently raised their price targets. With an FDA-approved pain medication, a partnership with generic giant Teva Pharmaceuticals and a superior pipeline, the stock may be an acquisition target. After a huge rise, the stock took a hit when CNBC’s Jim Cramer urged viewers to take profits. The company also had a bear raid from a short seller that was quickly refuted by the CEO.
The lowered price may offer new money a solid entry point.
The Maxim price target is $11, and the consensus target is at $7.33. Shares closed Thursday at $4.27.
http://247wallst.com/healthcare-business/2014/02/07/eight-bi…
Galena Biopharma announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 2014 Leerink Global Healthcare Conference. The presentation will take place on Wednesday, February 12, 2014 at 3:55 p.m. ET at the Waldorf Astoria Hotel in New York,
Hoffe das stimmt nicht...
"my sources just confirmed something very important about GALE
my sources just confirmed that Andrew Left is working on Gale ; he usually shorts high and after the stock drops 20% they will release short attack. let us longs work together and ask Brian Nicole to prepare pre emtive articles"
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
"my sources just confirmed something very important about GALE
my sources just confirmed that Andrew Left is working on Gale ; he usually shorts high and after the stock drops 20% they will release short attack. let us longs work together and ask Brian Nicole to prepare pre emtive articles"
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
Durchsuchen
